drugset / Trial / NCT01475981

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

NCT01475981

Phase 1 Completed 70 enrolled Akros Pharma Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to determine the safety, tolerability and pharmacokinetics of ascending single oral doses of JTK-853 administered under fasted or fed conditions in healthy male subjects.

Timeline

Start
2010-01
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject JTK-853 Small molecule Oral

Indications

No indication recorded.